HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists

March 21, 2023 updated by: Hospital for Special Surgery, New York

Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020

The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

143

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10021
        • Hospital for Special Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Accredited to practice at HSS
  • All anesthesiology and surgery faculty
  • All anesthesia and orthopedic surgery fellows
  • All orthopedic surgery residents

Exclusion Criteria:

• Refusal to participate in either of the interventions at either of the timepoints of interest

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With SARS-CoV-2 IgG Antibodies
Time Frame: Serology Test #1 (Study Enrollment) and Test #2 (3 months apart)
Prevalence of SARS-CoV-2 IgG antibodies by serology testing in participants at the time of study enrollment or 3 months later
Serology Test #1 (Study Enrollment) and Test #2 (3 months apart)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences in Sex Between IgG Antibody-positive vs. Negative Participants
Time Frame: Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as sex.
Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Number of Asymptomatic Participants With Positive Antibody Serology
Time Frame: Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)
Number of asymptomatic participants with positive antibody serology at either the study enrollment timepoint or 3 month timepoint
Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)
Percentage of Antibody-positive Participants Who Subsequently Develop COVID-19
Time Frame: Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)
Percentage of antibody-positive participants who subsequently develop COVID-19 at either the study enrollment timepoint or the 3 months time point
Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)
Differences in Race Between IgG Antibody-positive vs. Negative Participants
Time Frame: Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as race.
Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Differences in Average Number of Adults in Household Between IgG Antibody-positive vs. Negative Participants
Time Frame: Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as number of adult household members.
Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Differences in Comorbidities Between IgG Antibody-positive vs. Negative Participants
Time Frame: Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included comorbidities.
Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participants Who Were Eligible for in Plasma Donation
Time Frame: Serology Test #1 (Study Enrollment) and Test #2 (3 months apart)
Individuals who tested positive for COVID-19 who may be eligible for convalescent plasma donation
Serology Test #1 (Study Enrollment) and Test #2 (3 months apart)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital for Special Surgery, New York

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2020

Primary Completion (Actual)

June 16, 2020

Study Completion (Actual)

September 4, 2020

Study Registration Dates

First Submitted

May 8, 2020

First Submitted That Met QC Criteria

May 13, 2020

First Posted (Actual)

May 15, 2020

Study Record Updates

Last Update Posted (Estimated)

January 3, 2024

Last Update Submitted That Met QC Criteria

March 21, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-0850

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID

Clinical Trials on SARS-CoV2 serum antibody testing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe